Difference between revisions of "Binimetinib (Mektovi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
Line 12: | Line 12: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
− | |||
− | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
− | [[Category: | + | [[Category:MAP2K1 inhibitors]] |
+ | [[Category:MAP2K2 inhibitors]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] |
Revision as of 15:34, 16 August 2017
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.
Preliminary data
Melanoma
- Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56. Epub 2013 Feb 13. link to SD article PubMed
- Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Mar 8. [Epub ahead of print] link to original article PubMed
Also known as
ARRY-162, ARRY-438162